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Abstract
Evidence associating serum 25-hydroxyvitamin D (25(OH)D) concentrations and cardiometabolic risk factors is inconsistent and studies have
largely been conducted in adult populations. We examined the prospective associations between serum 25(OH)D concentrations and
cardiometabolic risk factors from adolescence to young adulthood in the West Australian Pregnancy Cohort (Raine) Study. Serum 25(OH)D
concentrations, BMI, homoeostasis model assessment for insulin resistance (HOMA-IR), TAG, HDL-cholesterol and systolic blood pressure
(SBP) were measured at the 17-year (n 1015) and 20-year (n 1117) follow-ups. Hierarchical linear mixed models with maximum likelihood
estimation were used to investigate associations between serum 25(OH)D concentrations and cardiometabolic risk factors, accounting for
potential confounders. In males and females, respectively, mean serum 25(OH)D concentrations were 73·6 (SD 28·2) and 75·4 (SD 25·9) nmol/l
at 17 years and 70·0 (SD 24·2) and 74·3 (SD 26·2) nmol/l at 20 years. Deseasonalised serum 25(OH)D3 concentrations were inversely associated
with BMI (coefficient −0·01; 95% CI −0·03, −0·003; P= 0·014). No change over time was detected in the association for males; for females, the
inverse association was stronger at 20 years compared with 17 years. Serum 25(OH)D concentrations were inversely associated with
log-HOMA-IR (coefficient −0·002; 95% CI −0·003, −0·001; P< 0·001) and positively associated with log-TAG in females (coefficient 0·002;
95% CI 0·0008, 0·004; P= 0·003). These associations did not vary over time. There were no significant associations between serum 25(OH)D
concentrations and HDL-cholesterol or SBP. Clinical trials in those with insufficient vitamin D status may be warranted to determine any
beneficial effect of vitamin D supplementation on insulin resistance, while monitoring for any deleterious effect on TAG.
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CVD is the leading cause of deaths related to non-communicable
diseases, and improving the detection and treatment of CVD is a
major goal of clinical medicine(1). Low serum 25-hydroxyvitamin D
(25(OH)D) concentrations are frequently reported in populations
worldwide(2–7), and there are a number of potential mechanisms
implicating low vitamin D status in cardiometabolic risk. There
appears to be a role for vitamin D in the development of insulin
resistance: vitamin D receptors are strongly expressed
in pancreatic β-cells(8), and the active form of vitamin D (1,25-
dihydroxyvitamin D) may protect against insulin resistance in
peripheral tissues such as skeletal muscle(9). Animal and in vitro
studies suggest that 1,25-dihydroxyvitamin D is a potent negative
regulator of renin gene expression and may prevent the over-
stimulation of the renin–angiotensin system(10) – a regulatory
pathway that plays an essential role in blood pressure.
A recent review of systematic reviews and meta-analyses
found that highly convincing evidence of a clear role of vitamin D
does not exist for CVD, hypertension or type 2 diabetes(11).
However, the epidemiological evidence associating serum
25(OH)D concentrations and cardiometabolic risk has been lar-
gely cross-sectional in design and focuses on adult populations,
with conflicting results. Using data from the 17- and
20-year follow-ups of the Western Australia Pregnancy Cohort
(Raine) Study, we investigated the prospective associations
Abbreviations: 25(OH)D, 25-hydroxyvitamin D; HC, hormonal contraception; HOMA-IR, homoeostasis model assessment for insulin resistance; SBP, systolic
blood pressure.
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between serum 25(OH)D concentrations and cardiometabolic
risk factors including BMI, insulin resistance, HDL-cholesterol,
TAG and systolic blood pressure (SBP). To our knowledge, this is
the first prospective study examining associations between serum
25(OH)D concentrations and cardiometabolic risk factors in
adolescents and young adults.
Methods
Participants
The Raine Study is a prospective, population-based, longitudinal
study and its methodology has been described previously(12). In
brief, a total of 2900 pregnant women from the public antenatal
clinic at King Edward Memorial Hospital and surrounding private
clinics in Perth, WA, were recruited between May 1989 and
November 1991, and they gave birth to 2868 live children. These
children underwent assessment at birth and at ages 1, 2, 3, 5, 8,
10, 14, 17 and 20 years. Recruitment and all follow-ups were
approved by the ethics committees of King Edward Memorial
Hospital for Women and the Princess Margaret Hospital for
Children, Perth, WA. Informed and written consent was obtained
from the participant and/or their primary caregiver at all follow-ups.
Serum 25-hydroxyvitamin D concentrations
Serum 25(OH)D concentrations were determined at the 17- and
20-year follow-ups. Venous blood samples were collected from an
antecubital vein after an overnight fast and stored at −80°C until
analysis. Serum 25(OH)D2 and 25(OH)D3 concentrations were
measured using isotope-dilution liquid chromatography tandem
MS (LC-MS/MS; RDDT), according to published methodology(13).
The method for the quantification of vitamin D metabolites (25
(OH)D2 and 25(OH)D3) in serum/plasma used hexa-deuterated
25(OH)D3 as an internal standard on either the API 4000 QTRAP
system (AB Sciex) or the Agilent 6410 QQQ LC-MS/MS system
(Aligent Technologies). Serum Calibration Standards containing
nominal amounts of 25(OH)D2/25(OH)D3 from Chromsystems
were used to generate calibration curves. Tri-level quality control
samples containing 25(OH)D2/25(OH)D3 designated as level low,
level 1 and level 2 were purchased from UTAK Laboratories
(PM Separations). At 17 years, the CV for 25(OH)D3 was 7·1% at
27nmol/l, 5·0% at 75nmol/l and 5·3% at 164nmol/l, and the CV
for 25(OH)D2 was 8·8% at 23nmol/l, 6·7% at 66nmol/l and 6·7%
at 150nmol/l. At 20 years, the CV for 25(OH)D3 was 5·8% at
28nmol/l, 5·2% at 80nmol/l and 9·2% at 188nmol/l, and the CV
for 25(OH)D2 was 7·9% at 25nmol/l, 6·6% at 75nmol/l and 10·4%
at 185nmol/l.
Cardiometabolic risk factors
Participants at 17 years were weighed to the nearest 100 g using
a Wedderburn Digital Chair Scale, and height was determined
to the nearest 0·1 cm using a Holtain Stadiometer. At 20 years,
weight was measured to the nearest 100 g using Personal
Precision scales UC-321 (A&D Company), and height was
measured to the nearest 0·1 cm using a wall-mounted Seca 202.
BMI was calculated as weight in kilograms divided by height in
metres squared. Fasting blood samples at the 17- and 20-year
follow-ups were analysed for serum glucose, HDL-cholesterol
and TAG, determined enzymatically using an Architect c16000
Analyser (Abbott Laboratories) (intra-assay CV were 1·0% for
glucose, 2·0% for HDL-cholesterol and 1·9% for TAG). Serum
insulin was determined using an Architect i2000SR Analyser
(intra-assay CV 1·78%) (Abbott Laboratories). The homoeostasis
model assessment for insulin resistance (HOMA-IR) score
was calculated as follows: HOMA-IR score= (fasting insulin
(μU/ml)× fasting glucose (mmol/l))/22·5(14). Resting blood
pressure at 17 and 20 years was obtained using an oscillometric
sphygmomanometer (Dinamap ProCare 100; Soma Techno-
logy). After 5min of quiet rest, six automatic recordings were
taken every 2min with subjects in the supine position and with
an appropriate cuff size. The averages of the last five readings
of SBP were calculated.
Potential confounding variables
Participants were classified as Caucasian if both parents were
Caucasian, or as non-Caucasian if one or both parents were of
an alternate ethnicity. Physical activity at the 17-year follow-up
was assessed using a self-reported questionnaire based on
exercise outside of school hours per week, with exercise
defined in three categories as activity causing breathlessness or
sweating (≥4 times/week, 1–3 times/week and <once per
week). At 20 years, physical activity was assessed using a
self-reported questionnaire that recorded time spent in moder-
ate or vigorous physical activity (≥4 times/week, 1–3 times/
week and <once per week).
A baseline measure of family income was available at the
17-year follow-up, completed by the primary caregiver, with
twelve categories ranging from $1–$8000/year to ≥$104000/year
(Australian dollars). At the 17- and 20-year follow-ups, the parti-
cipants answered the question ‘do you currently smoke cigarettes’.
At the 17- and 20-year follow-ups, the use of hormonal
contraception (HC) (yes/no) was reported by the participant.
A self-reported, semi-quantitative FFQ developed by the
Commonwealth Scientific and Industrial Research Organisation
in Adelaide, Australia(15), was used at the 17-year follow-up to
assess alcohol intake (g/d). This 212-item FFQ assesses usual
dietary intake over the previous year, collecting information on
the frequency of consumption of individual foods, mixed dishes
and beverages, along with information on usual serving sizes in
relation to a standard serving size (in household units).
Participants were asked how often they usually drank six types
of alcohol (low-alcohol beer, regular beer, alcoholic soda,
wine/champagne, sherry/port/liqueur and spirits). Frequency
was recorded as never, rarely, times per month, times per week
or times per day.
At the 20-year follow-up, alcohol intake (g/d) was assessed
using a self-reported, semi-quantitative FFQ developed by the
Anti-Cancer Council of Victoria for use in the ethnically diverse
Australian population(16). The questionnaire includes three
questions on alcohol consumed over the last 12 months.
Participants were asked to report how often they drank beer,
wine and/or spirits, with six types of alcohol specified
(low-alcohol beer, full-strength beer, red wine, white/sparkling
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wine, fortified wine, spirits/liqueurs) and ten frequency choices
ranging from ‘never’ to ‘every day’. A second question asked
how many glasses of beer/wine and/or spirits they usually
drank on days they were drinking (total number of glasses
per day, ranging from one to ten or more). A third question
asked about the maximum number of glasses of beer/wine
and/or spirits they drank in 24 h (maximum number of glasses
per 24 h ranging from one to two to nineteen or more).
Addressing potential seasonal effects
Models investigating HDL-cholesterol, TAG and HOMA-IR were
not adjusted for season as these biomarkers change relatively
quickly over time, and the blood samples for these biomarkers
were collected on the same day as that for the measurement of
serum 25(OH)D concentrations. Similarly, SBP changes relatively
quickly over time, and it would not be appropriate to adjust for
season if serum 25(OH)D concentrations and SBP measurements
were taken on the same day. Although 95% of participants had
blood samples for serum 25(OH)D concentrations and SBP
measurements taken within 31d of each other, approximately 5%
of the participants had measurements taken > 31d apart. In order
to determine whether the time difference between measurement
of serum 25(OH)D concentrations and SBP influenced the asso-
ciation between serum 25(OH)D concentrations and SBP, we
deseasonalised the serum 25(OH)D3 concentrations using sine
and cosine curves(17) and moved the projected date back to
match the day SBP was measured. This technique has previously
been reported by Lucas et al.(18). For models investigating BMI,
which changes relatively slowly over time, we used deseasona-
lised serum 25(OH)D3 concentrations
(17).
Statistical analyses
Characteristics of the participants for whom full data for cardio-
metabolic risk factors and HC were available were described at
both the 17- and 20-year follow-ups. A three-level variable for sex
(to distinguish females not using HC, females using HC and
males) was used to assess the interactive effects of HC use on the
relationship between serum 25(OH)D concentrations and all
outcomes, except BMI. For BMI, there was no difference between
females not using HC and females using HC. Additional power
was required to demonstrate statistically significant differences
between females and males; therefore, for the BMI model, we
used a two-level variable for sex. HOMA-IR, TAG and
HDL-cholesterol were not normally distributed, and therefore
log-transformations were applied.
Hierarchical linear mixed models with maximum likelihood
estimation (MLE) were used to investigate associations between
serum 25(OH)D concentrations and cardiometabolic risk factors
(BMI, HOMA-IR, TAG, HDL-cholesterol, SBP) over time. All
models included adjustment for sex and BMI (excluding the
model with BMI as an outcome) and investigated possible
interactions between time, serum 25(OH)D concentrations and
each of sex or BMI. The hierarchical structure accounted for
potential correlation between a small number of siblings.
Additional covariates (race, physical activity, family income,
smoking status, alcohol intake and month of birth) were then
included individually to determine whether a significant
association with the outcome was detected or whether the
covariate influenced any relationship between serum 25(OH)D
concentrations and the outcome. Sample sizes were held fixed
for these comparisons based on the sample without missing
data for each covariate in turn. Owing to considerable missing
data for some covariates, models utilising MLE for covariates
(structural equation models in Stata) were also used to inves-
tigate possible bias the loss of sample may have introduced.
These models were not longitudinal models but rather
approximations achieved by identifying repeated measures on
the subject as a per person cluster, resulting in an adjusted,
robust variance. The sibling adjustment was not made in
these models. These models were used to determine whether
multiple imputation was necessary.
Although some of the additional covariates were significantly
associated with the outcomes, the analysis determined that
these associations were independent of the relationship
with serum 25(OH)D concentrations. The significance of the
relationship between serum 25(OH)D concentrations and
the outcome was unaltered by the inclusion of the additional
covariates, and variations in the magnitude of the relationships
(the coefficient) were considered to be minimal (online
Supplementary Tables S1 and S2). Hence, it was determined
that multiple imputation to facilitate inclusion of variables that
had no effect on the relationship of interest was unnecessary.
Analyses were performed using IBM SPSS Statistics Release
version 19.9.9.1 (IBM SPSS Inc., 2010) and StataCorp 2011 Stata
Statistical Software: Release 12 (StataCorp LP). Statistical
significance was defined as two-tailed P< 0·05. The regression
tables are reported per 1 nmol/l change in serum 25(OH)D
concentrations and as log-transformations of HOMA-IR, TAG
and HDL-cholesterol.
Results
Participant characteristics
Full data for outcome variables and HC were available for 1015
participants at the 17-year follow-up and for 1117 participants at
the 20-year follow-up. A CONSORT flow diagram is shown in
Fig. 1, and participant characteristics for males and females are
shown in Table 1. Mean serum 25(OH)D concentrations were
73·6 (SD 28·2) and 75·4 (SD 25·9) nmol/l at the 17-year follow-up
in males and females, respectively and were 70·0 (SD 24·2) and
74·3 (SD 26·2) nmol/l at the 20-year follow-up in males and
females, respectively. At the 17-year follow-up, only four
participants had detectable serum 25(OH)D2 concentrations,
ranging from 5·44 to 8·12 nmol/l. At the 20-year follow-up,
thirteen participants had detectable serum 25(OH)D2
concentrations, ranging from 5·24 to 7·07 nmol/l.
Deseasonalised serum 25-hydroxyvitamin D3
concentrations and BMI
In a univariate analysis, deseasonalised serum 25(OH)D3
concentrations were inversely associated with BMI (coefficient
−0·02; 95% CI −0·03, −0·02; P< 0·001) and the association
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persisted after adjusting for sex (Table 2). A significant three-
way interaction between time, sex and serum 25(OH)D3
concentrations indicated that the relationship between serum
25(OH)D3 concentrations and BMI changed over time differ-
ently in males compared with females (P= 0·026). No change
over time was detected in the association for males, whereas for
females the inverse association was stronger at 20 years com-
pared with 17 years (Fig. 2). The model estimates that a 1 SD
increase in serum 25(OH)D3 concentration (approximately
25nmol/l) was associated with a reduction in BMI of 0·4kg/m2 in
females at 17 years, 0·6kg/m2 in females at 20 years,
0·6kg/m2 in males at 17 years, and 0·5kg/m2 in males at 20 years.
Serum 25-hydroxyvitamin D concentrations and insulin
resistance
In a univariate model, serum 25(OH)D concentrations were
inversely associated with log-HOMA-IR (coefficient −0·003;
95% CI −0·005, −0·002; P< 0·001) and the inverse association
was maintained after adjusting for BMI (coefficient −0·002; 95%
CI −0·003, −0·001; P< 0·001) (Table 3). No significant inter-
actions were found between time, serum 25(OH)D concentra-
tions and each of sex or BMI. The model estimates that a 1 SD
increase in serum 25(OH)D concentrations was associated
with a 5% decrease in HOMA-IR.
Serum 25-hydroxyvitamin D concentrations and TAG
In a univariate model, serum 25(OH)D concentrations
were positively associated with log-TAG (coefficient= 0·001;
95% CI 0·0004, 0·002; P= 0·03). A significant interaction
between serum 25(OH)D concentrations and sex indicated that
the relationship between serum 25(OH)D concentrations and
log-TAG differed in males when compared with females
(P= 0·016). There was a positive association in females not
using HC after adjusting for BMI (coefficient 0·0023; 95% CI
0·0008, 0·0038; P= 0·003) (Table 4), as well as a similar effect in
females using HC. Coefficients from the model estimate that a
1 SD increase in serum 25(OH)D concentrations was associated
with a 6% increase in TAG in females. There was no significant
association between serum 25(OH)D concentrations and TAG
in males (P= 0·738).
Serum 25-hydroxyvitamin D concentrations and
HDL-cholesterol
Serum 25(OH)D concentrations were positively associated with
log-HDL-cholesterol in a univariate model (coefficient 0·0005;
95% CI 0·0002, 0·0008; P= 0·004). However, there was no
association between serum 25(OH)D concentrations and
HDL-cholesterol after adjusting for BMI (online Supplementary
Table S3), and no significant interactions were found between
time, serum 25(OH)D concentrations and each of sex or BMI.
Serum 25-hydroxyvitamin D concentrations and systolic
blood pressure
There was no difference in the relationship between serum
25(OH)D concentrations and SBP when we moved the
projected date of blood measurement back to match the day
SBP was measured. Therefore, we did not deseasonalise serum
25(OH)D concentrations or adjust for season in models with
SBP as the outcome measure. An inverse association between
serum 25(OH)D concentrations and SBP (coefficient −0·02;
95% CI −0·04, −0·003; P = 0·023) in a univariate analysis was
not significant after adjusting for BMI (online Supplementary
Table S4). No significant interactions were found between time,
serum 25(OH)D concentrations and each of sex or BMI.
Discussion
This study has shown that serum 25(OH)D concentrations are
inversely associated with BMI and HOMA-IR in an adolescent
and young adult population. Serum 25(OH)D concentrations
were positively associated with TAG in females only. There
were no significant associations between serum 25(OH)D
concentrations and HDL-cholesterol or SBP.
The inverse association between deseasonalised serum
25(OH)D3 concentrations and BMI was consistent between
17 and 20 years in males, but increased over time in females.
Similarly, an inverse association between serum 25(OH)D
concentrations and waist circumference was identified
by Gagnon et al.(19) in a prospective study of 4164 adults
participating in The Australian Diabetes, Obesity and Lifestyle
(AusDiab) Study and by Ganji et al.(20) in a cross-sectional
study of 5867 adolescents participating in the US National
Health and Nutrition Examination Survey (NHANES).
1047 (from 1013
families) with BMI,
hormonal
contraceptive use
and SBP
1127 (from 1083
families) with BMI,
hormonal
contraceptive use
and SBP
1015 (from 982
families) with
HOMA-IR,
HDL-cholesterol
and TAG
1754 attended 17
year follow-up
1268 with serum
25(OH)D
concentrations
1473 attended 20
year follow-up
1172 with serum
25(OH)D
concentrations
1117 (from 1073
families) with
HOMA-IR,
HDL-cholesterol
and TAG
2868 Raine Study
802 common
to both years
782 common
to both years
Fig. 1. CONSORT flow diagram. 25(OH)D, 25-hydoxyvitamin D; SBP, systolic
blood pressure; HOMA-IR, homoeostasis model assessment for insulin
resistance.
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We found a significant inverse association between serum
25(OH)D concentrations and HOMA-IR, a result that is
supported by a number of other studies in children and
adolescents(20–26), including the study by Ganji et al.(20). The
prospective study by Gagnon et al.(19) also found that serum
25(OH)D concentrations were inversely associated with
HOMA-IR in adults. However, Nam et al.(27) found no
significant associations between serum 25(OH)D concentrations
and insulin resistance or fasting glucose in a cross-sectional study
of 1504 children and adolescents participating in the Korean
NHANES, after adjusting for age, sex, physical activity, alcohol
consumption and supplement use. Although a 6-month trial
supplementing 4000 IU/d (100μg/d) of vitamin D in thirty-five
obese adolescents found significant improvements in HOMA-IR
compared with placebo(28), vitamin D supplementation trials in
adults have shown mixed results on glycaemic status, insulin
resistance and insulin sensitivity(29–41).
There may be associations between vitamin D responsiveness,
vitamin D-receptor (VDR) gene polymorphisms and insulin
resistance. Associations between SNP and responses in insulin
sensitivity to vitamin D supplementation of 4000 IU/d (100 μg/d)
were determined in eighty-one South Asian women(42). The
improvement in insulin sensitivity was significantly greater in
women with the FokI Ff genotype compared with women with
the FokI FF genotype. Therefore, differences in the VDR gene
may explain differences in response of insulin sensitivity to
vitamin D supplementation. Further explorations of the influence
of SNP on responsiveness of cardiometabolic risk factors to
vitamin D intervention are warranted.
We found a positive association between serum 25(OH)D
concentrations and TAG in females. Other observational
studies have shown an inverse association(19,43), or no
association(27), between circulating 25(OH)D concentrations
and TAG. However, our finding was supported by a recent
Table 1. Characteristics of the Raine Study participants for whom full data on outcome variables and hormonal contraceptive use were available
(Numbers and percentages; mean values and standard deviations; medians and interquartile ranges (IQR))
17-year follow-up (n 1015) 20-year follow-up (n 1117)
Male Female Male Female
n % n % n % n %
Race (Caucasian) 453 85 407 85 505 84 447 86
Serum 25(OH)D (nmol/l) 534 481 598 519
Mean 73·6 75·4 70·0 74·3
SD 28·2 25·9 24·2 26·2
HOMA-IR 534 481 598 519
Median 1·5 1·6 0·5 0·6
IQR 1·3 1·3 0·7 0·9
Total cholesterol (mmol/l) 534 481 598 519
Mean 3·9 4·3 4·2 4·5
SD 0·7 0·7 0·8 0·8
LDL-cholesterol (mmol/l) 534 481 598 519
Mean 2·2 2·4 2·4 2·6
SD 0·7 0·6 0·7 0·6
HDL-cholesterol 534 481 598 519
Median 1·2 1·4 1·2 1·4
IQR 0·3 0·4 0·3 0·4
TAG (mmol/l) 534 481 598 519
Median 0·9 0·9 1·0 1·0
IQR 0·5 0·5 0·6 0·6
SBP (mmHg) 534 481 598 519
Mean 120·2 110·1 123·4 111·4
SD 10·2 9·6 12·6 11·2
BMI (kg/m2) 534 481 598 519
Mean 22·8 23·2 24·5 24·3
SD 4·3 4·6 2·5 5·4
Physical activity
≥4 times/week 143 33 77 18 329 73 218 47
1–3 times/week 273 54 231 53 75 17 141 30
< once per week 59 13 125 29 47 10 107 23
Family income at 17 years
≤$40000/year 119 25 125 28 NR NR NR NR
$40001–78 000/year 176 37 172 38 NR NR NR NR
>$78000/year 185 39 151 34 NR NR NR NR
Hormonal contraceptive use (current user) NA NA 155 32 NA NA 308 59
Smoking status (current smoker) 96 19 111 23 73 16 62 13
Alcohol consumers 201 59 201 56 511 92 469 94
Alcohol intake in consumers (g/d)
Median 6·0 5·4 15·9 8·4
IQR 12·3 8·9 30·0 16·4
25(OH)D, 25-hydroxyvitamin D; HOMA-IR, homoeostasis model assessment for insulin resistance; SBP, systolic blood pressure; NR, not reported.
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randomised-controlled trial in 200 hypertensive adults with low
serum 25(OH)D concentrations: Pilz et al.(44) showed that
vitamin D supplementation significantly increased TAG compared
with placebo. Although the authors hypothesised that this result
was a chance finding, they noted that further validation from
additional studies is warranted. In contrast, a trial in 200 healthy
overweight subjects participating in a 12-month weight-reduction
programme found that, compared with the placebo group,
vitamin D supplementation lowered TAG but increased
LDL-cholesterol(45). We found no statistically significant associations
between serum 25(OH)D concentrations and HDL-cholesterol,
which is supported by the studies by Nam et al.(27) and Gagnon
et al.(19). A recent review of vitamin D supplementation and lipid
profile found that most randomised-controlled trials showed no
effects, or even adverse effects, on serum lipids(46).
We found no independent association between serum
25(OH)D concentrations and SBP. This finding conflicts with
a systematic review and meta-analysis of twenty-two
cross-sectional studies and eight prospective studies (largely
in adult populations), which showed that circulating 25(OH)D
concentrations were inversely associated with risk of hyper-
tension(47). However, the results of vitamin D supplementation
trials and SBP are equivocal. A meta-analysis of sixteen
randomised trials on the effects of vitamin D supplementation
on blood pressure in adults showed an overall non-significant
reduction in both SBP and diastolic blood pressure(48). The trial
by Pilz et al.(44) showed that vitamin D supplementation had no
significant effect on SBP.
There is growing interest in the health effects of sun exposure
beyond the synthesis of vitamin D, and it is plausible that serum
Table 2. Adjusted associations between deseasonalised serum 25-hydroxyvitamin D3 (25(OH)D3) concentrations and BMI
(Coefficients and 95% confidence intervals)
Variables Coefficient* 95% CI P
Deseasonalised 25(OH)D3 (nmol/l) −0·01† −0·03, −0·003 0·014
Time
20-year follow-up 1·96 1·08, 2·85 <0·001
Sex
Male 0·33 −0·94, 1·61 0·610
Time×25(OH)D3
20-year follow-up −0·01 −0·02, −0·0002 0·047
Time× sex
Male (20 years) −0·82 −2·02, 0·39 0·182
Sex× 25(OH)D3
Male −0·01 −0·03, 0·005 0·190
Time× sex × 25(OH)D3
Male (20 years) 0·02 0·002, 0·03 0·026
Constant 24·47 23·52, 25·42 <0·001
* Estimated difference in BMI from the reference category of categorical variables or per 1 unit increase of continuous variables.
† Shown in the Table is the coefficient for females, 17-year follow-up. Females, 20-year follow-up: coefficient −0·03; 95% CI −0·04, −0·02; P<0·001. Males,
17-year follow-up: coefficient −0·03; 95% CI −0·04, −0·01; P<0·001. Males, 20-year follow-up: coefficient −0·02; 95% CI −0·03, −0·01; P=0·001.
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Fig. 2. A graphical representation of the three-way interaction in the BMI model showing an inverse association between deseasonalised serum 25-hydoxyvitamin D3
concentrations and BMI that does not change over time in males, but is stronger in females, at 20 years compared with 17 years. 25(OH)D, 25-hydoxyvitamin D.
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25(OH)D concentrations are merely a biomarker of previous
sun exposure. Recent in vivo experiments indicate that chronic
skin exposure to low-dose UV radiation (UVR) limits the
development of obesity and signs of the metabolic syndrome in
mice fed a high-fat diet(49). Skin exposure to UVR induces several
immune effector molecules, and low-dose UVR irradiation of
the skin has been shown to lower blood pressure in healthy
volunteers, independently of vitamin D, through modulation of
nitric oxide bioavailability(50). Further investigations to elucidate
the vitamin D-independent effects of low-dose exposure to UVR
on cardiometabolic risk factors are warranted.
Strengths of our study include the young age of the cohort
and the prospective design based on a longitudinal cohort. We
were able to investigate confounders that potentially impact
upon serum 25(OH)D concentrations and cardiometabolic risk
factors, including race, month of birth, BMI, physical activity,
family income, hormonal contraceptive use, smoking status and
alcohol intake. However, despite our best efforts to adjust for
confounders, we cannot rule out the possibility of residual
confounding. Weaknesses of our study include the measure-
ment of physical activity, which was not based on a validated
questionnaire and may be subject to self-reporting bias.
Furthermore, our assessment of physical activity did not
differentiate between indoor and outdoor activities. The
non-significance of physical activity in relation to cardiometa-
bolic risk factors may reflect the limitations of the measurement,
rather than the true absence of an association between physical
activity and the outcome. In light of the evidence associating
genetic factors with responses in insulin resistance to vitamin D
supplementation(42), it is possible that genetic variation may
modify the association between serum 25(OH)D concentrations
and cardiometabolic risk factors. In our study, no data were
available for genetic factors relating to vitamin D; further studies
in this area would benefit from investigating factors such as the
FokI Ff genotype.
Although we used the same laboratory for measuring serum
25(OH)D concentrations using LC-MS/MS methods at both
follow-ups, this laboratory was not participating in an external
quality control scheme at the time of analysis. Laboratories
using LC-MS/MS methods have been shown to give higher
results than those certified to the international standard
reference method developed by the National Institute of
Standards and Technology and Ghent University(51), which may
have partly contributed to the relatively high serum 25(OH)D
Table 3. Adjusted associations between serum 25-hydroxyvitamin D (25(OH)D) concentrations and log-homoeostasis model
assessment for insulin resistance
(Coefficients and 95% confidence intervals)
Variables Coefficient* 95% CI P
25(OH)D (nmol/l) −0·002 −0·003, −0·001 <0·001
Time
17-year follow-up Ref.
20-year follow-up −0·86 −0·91, −0·81 <0·001
Sex
Female Ref.
Female using HC 0·18 0·10, 0·26 <0·001
Male 0·01 −0·06, 0·08 0·814
BMI (kg/m2) 0·06 0·06, 0·07 <0·001
Constant −0·93 −1·11, −0·74 <0·001
Ref., referent values; HC, hormonal contraception.
* Estimated difference in log-homoeostasis model assessment for insulin resistance from the reference category of categorical variables or per 1 unit
increase of continuous variables.
Table 4. Adjusted associations between serum 25-hydroxyvitamin D (25(OH)D) concentrations and log-TAG
(Coefficients and 95% confidence intervals)
Variables Coefficient* 95% CI P
25(OH)D (nmol/l) 0·0023† 0·0008, 0·0038 0·003
Time
20-year follow-up −0·12 −0·17, −0·06 <0·001
Sex
Female using HC 0·24 0·08, 0·40 0·003
Male 0·25 0·12, 0·39 <0·001
Time× sex
Female using HC (20 years) 0·08 −0·01, 0·17 0·070
Male (20 years) 0·11 0·04, 0·18 0·001
Sex× 25(OH)D
Female using HC 0·0003 −0·0021, 0·0016 0·779
Male −0·0021 −0·0038, −0·0004 0·016
BMI (kg/m2) 0·03 0·02, 0·03 <0·001
Constant −0·95 −1·11, −0·80 <0·001
HC, hormonal contraception.
* Estimated difference in log-TAG from the reference category of categorical variables or per 1 unit increase of continuous variables.
† Shown in the Table is the coefficient for females not using HC. Males: coefficient= 0·00015; 95% CI −0·0008, 0·001; P=0·738.
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concentrations in our population. Given that our population of
adolescents/young adults has relatively high vitamin D status in
comparison with those in other countries(52), our findings may
not be generalisable to all populations. Furthermore, although
the availability of data from two cohort follow-ups in adoles-
cence and young adulthood enabled us to examine changes
over time, we cannot infer causality in the relationship between
serum 25(OH)D concentrations and cardiometabolic risk
factors.
Our results show that serum 25(OH)D concentrations are
independently associated with a number of cardiometabolic
risk factors in adolescents and young adults, with differential
effects on BMI with time between sexes. In particular, the
finding that serum 25(OH)D concentrations were inversely
associated with BMI and insulin resistance would suggest
a cardio-protective benefit, but this may be offset by the posi-
tive association between serum 25(OH)D concentrations and
TAG. Well-designed clinical trials in those with insufficient
vitamin D status may be warranted to determine any causal,
beneficial effect of vitamin D supplementation on insulin
resistance in adolescents and young adults, while monitoring
for any deleterious effect on TAG.
Acknowledgements
The authors gratefully acknowledge the Raine Study partici-
pants and their families. The authors also thank the Raine Study
Team for cohort coordination and data collection.
Core funding for the Raine Study is provided by the
University of Western Australia; the Faculty of Medicine,
Dentistry and Health Sciences at the University of Western
Australia; the Telethon Kids Institute; the Women and Infants
Research Foundation; Curtin University; and the Raine Medical
Research Foundation. Data collection and biological specimens
at the 17-year follow-up were funded by the National Health
and Medical Research Council (Programme grant ID 353514
and Project grant ID 403981) and the Ada Bartholomew Medical
Research Trust. Data collection for the 20-year follow-up was
funded by the National Health and Medical Research Council
Project ID 1022134.
T. A. M., L. J. Beilin and W. H. O. designed the study; T. A. M.,
L. J. Beilin and W. H. O. conducted the study; P. G. H. provided
essential reagents or provided essential materials; S. B. and
L. J. Black analysed the data; L. J. Black, S. B. and T. A. M. wrote
the paper; C. E. M., R.-C. H., W. C. S. P.-D., R. M. L. and P. H. H.
provided critical revision of the manuscript for important
intellectual content; T. A. M. had primary responsibility for the
final content. All the authors read and approved the final
version of the manuscript.
The authors have no potential conflicts of interest.
Supplementary material
For supplementary material/s referred to in this article, please
visit http://dx.doi.org/10.1017/S0007114516001185
References
1. Hunter DJ & Reddy KS (2013) Noncommunicable diseases.
N Engl J Med 369, 1336–1343.
2. Andersen R, Molgaard C, Skovgaard LT, et al. (2005) Teenage
girls and elderly women living in northern Europe have low
winter vitamin D status. Eur J Clin Nutr 59, 533–541.
3. Cashman KD, Muldowney S, McNulty B, et al. (2012)
Vitamin D status of Irish adults: findings from the national
adult nutrition survey. Br J Nutr 109, 1248–1256.
4. Forrest KY & Stuhldreher WL (2011) Prevalence and correlates
of vitamin D deficiency in US adults. Nutr Res 31, 48–54.
5. Looker AC, Johnson CL, Lacher DA, et al. (2011) Vitamin D
status: United States, 2001–2006. NCHS Data Brief 59, 1–8.
6. Whiting SJ, Langlois KA, Vatanparast H, et al. (2011) The
vitamin D status of Canadians relative to the 2011 dietary
reference intakes: an examination in children and adults with
and without supplement use. Am J Clin Nutr 94, 128–135.
7. Australian Bureau of Statistics (2014) Australian Health
Survey: Biomedical Results for Nutrients. Canberra: Australian
Bureau of Statistics.
8. Wang Y, Zhu J & DeLuca HF (2012) Where is the vitamin D
receptor? Arch Biochem Biophys 523, 123–133.
9. Dirks-Naylor AJ & Lennon-Edwards S (2011) The effects of
vitamin D on skeletal muscle function and cellular signaling.
J Steroid Biochem Mol Biol 125, 159–168.
10. Li YC (2003) Vitamin D regulation of the renin-
angiotensin system. J Cell Biochem 88, 327–331.
11. Theodoratou E, Tzoulaki I, Zgaga L, et al. (2014) Vitamin D
and multiple health outcomes: umbrella review of systematic
reviews and meta-analyses of observational studies and
randomised trials. BMJ 348, g2035.
12. Newnham JP, Evans SF, Michael CA, et al. (1993) Effects of
frequent ultrasound during pregnancy: a randomised
controlled trial. Lancet 342, 887–891.
13. Maunsell Z, Wright DJ & Rainbow SJ (2005) Routine isotope-
dilution liquid chromatography-tandem mass spectrometry
assay for simultaneous measurement of the 25-hydroxy
metabolites of vitamins D2 and D3. Clin Chem 51, 1683–1690.
14. Matthews DR, Hosker JP, Rudenski AS, et al. (1985) Home-
ostasis model assessment: insulin resistance and beta-cell
function from fasting plasma glucose and insulin
concentrations in man. Diabetologia 28, 412–419.
15. Baghurst KI & Record SJ (1984) A computerised dietary
analysis system for use with diet diaries or food frequency
questionnaires. Community Health Stud 8, 11–18.
16. Ireland P, Jolley D & Giles GG (1994) Development of the
Melbourne FFQ: a food frequency questionnaire for use in
an Australian prospective study involving an ethnically
diverse cohort. Asia Pac J Clin Nutr 3, 19–31.
17. van der Mei IA, Ponsonby AL, Dwyer T, et al. (2007) Vitamin
D levels in people with multiple sclerosis and community
controls in Tasmania, Australia. J Neurol 254, 581–590.
18. Lucas RM, Ponsonby AL, Dear K, et al. (2011) Sun exposure
and vitamin D are independent risk factors for CNS demyeli-
nation. Neurology 76, 540–548.
19. Gagnon C, Lu ZX, Magliano DJ, et al. (2012) Low serum
25-hydroxyvitamin D is associated with increased risk of the
development of the metabolic syndrome at five years: results
from a national, population-based prospective study (The
Australian Diabetes, Obesity and Lifestyle Study: AusDiab).
J Clin Endocrinol Metab 97, 1953–1961.
20. Ganji V, Zhang X, Shaikh N, et al. (2011) Serum
25-hydroxyvitamin D concentrations are associated with
prevalence of metabolic syndrome and various cardiometa-
bolic risk factors in US children and adolescents based
25-hydroxyvitamin D and cardiometabolic risk 2001
on assay-adjusted serum 25-hydroxyvitamin D data from
NHANES 2001–2006. Am J Clin Nutr 94, 225–233.
21. Brenner DR, Arora P, Garcia-Bailo B, et al. (2011) Plasma
vitamin D levels and risk of metabolic syndrome in Canadians.
Clin Invest Med 34, E377.
22. Buyukinan M, Ozen S, Kokkun S, et al. (2012) The relation of
vitamin D deficiency with puberty and insulin resistance in
obese children and adolescents. J Pediatr Endocrinol Metab
25, 83–87.
23. Kelly A, Brooks LJ, Dougherty S, et al. (2011) A cross-sectional
study of vitamin D and insulin resistance in children. Arch Dis
Child 96, 447–452.
24. Pacifico L, Anania C, Osborn JF, et al. (2011) Low 25(OH)D3
levels are associated with total adiposity, metabolic syndrome,
and hypertension in Caucasian children and adolescents.
Eur J Endocrinol 165, 603–611.
25. Nsiah-Kumi PA, Erickson JM, Beals JL, et al. (2012) Vitamin D
insufficiency is associated with diabetes risk in Native
American children. Clin Pediatr (Phila) 51, 146–153.
26. Hirschler V, Maccallinni G, Gilligan T, et al. (2012) Association
of vitamin D with insulin resistance in Argentine boys: a
pilot study. J Pediatr Biochem 2, 91–99.
27. Nam GE, Kim DH, Cho KH, et al. (2012) 25-Hydroxyvitamin D
insufficiency is associated with cardiometabolic risk in Korean
adolescents: the 2008–2009 Korea National Health and
Nutrition Examination Survey (KNHANES). Public Health
Nutr 17, 186–194.
28. Belenchia AM, Tosh AK, Hillman LS, et al. (2013) Correcting
vitamin D insufficiency improves insulin sensitivity in obese
adolescents: a randomized controlled trial. Am J Clin Nutr 97,
774–781.
29. Beilfuss J, Berg V, Sneve M, et al. (2012) Effects of a 1-year
supplementation with cholecalciferol on interleukin-6, tumor
necrosis factor-alpha and insulin resistance in overweight and
obese subjects. Cytokine 60, 870–874.
30. Eftekhari MH, Akbarzadeh M, Dabbaghmanesh MH, et al.
(2011) Impact of treatment with oral calcitriol on glucose
indices in type 2 diabetes mellitus patients. Asia Pac J Clin
Nutr 20, 521–526.
31. Harris SS, Pittas AG & Palermo NJ (2012) A randomized,
placebo-controlled trial of vitamin D supplementation
to improve glycaemia in overweight and obese African
Americans. Diabetes Obes Metab 14, 789–794.
32. Mitri J, Dawson-Hughes B, Hu FB, et al. (2011) Effects of
vitamin D and calcium supplementation on pancreatic β cell
function, insulin sensitivity, and glycemia in adults at high risk
of diabetes: the Calcium and Vitamin D for Diabetes Mellitus
(CaDDM) randomized controlled trial. Am J Clin Nutr 94,
486–494.
33. Nagpal J, Pande JN & Bhartia A (2009) A double-blind,
randomized, placebo-controlled trial of the short-term effect
of vitamin D3 supplementation on insulin sensitivity in
apparently healthy, middle-aged, centrally obese men.
Diabet Med 26, 19–27.
34. Nikooyeh B, Neyestani TR, Farvid M, et al. (2011) Daily
consumption of vitamin D- or vitamin D+ calcium-fortified
yogurt drink improved glycemic control in patients with
type 2 diabetes: a randomized clinical trial. Am J Clin Nutr 93,
764–771.
35. Patel P, Poretsky L & Liao E (2010) Lack of effect of
subtherapeutic vitamin D treatment on glycemic and lipid
parameters in type 2 diabetes: a pilot prospective
randomized trial. J Diabetes 2, 36–40.
36. Shab-Bidar S, Neyestani TR, Djazayery A, et al. (2011) Regular
consumption of vitamin D-fortified yogurt drink (Doogh)
improved endothelial biomarkers in subjects with type 2 diabetes:
a randomized double-blind clinical trial. BMC Med 9, 125.
37. von Hurst PR, Stonehouse W & Coad J (2010) Vitamin D
supplementation reduces insulin resistance in South Asian
women living in New Zealand who are insulin resistant and
vitamin D deficient – a randomised, placebo-controlled trial.
Br J Nutr 103, 549–555.
38. Witham MD, Dove FJ, Dryburgh M, et al. (2010) The effect of
different doses of vitamin D(3) on markers of vascular health
in patients with type 2 diabetes: a randomised controlled trial.
Diabetologia 53, 2112–2119.
39. Wood AD, Secombes KR, Thies F, et al. (2012) Vitamin D3
supplementation has no effect on conventional cardiovascular
risk factors: a parallel-group, double-blind, placebo-
controlled RCT. J Clin Endocrinol Metab 97, 3557–3568.
40. Grimnes G, Figenschau Y, Almas B, et al. (2011) Vitamin D,
insulin secretion, sensitivity, and lipids: results from a
case-control study and a randomized controlled trial using
hyperglycemic clamp technique. Diabetes 60, 2748–2757.
41. Zhu W, Cai D, Wang Y, et al. (2013) Calcium plus vitamin D3
supplementation facilitated fat loss in overweight and
obese college students with very-low calcium consumption:
a randomized controlled trial. Nutr J 12, 8.
42. Jain R, von Hurst PR, Stonehouse W, et al. (2012) Association
of vitamin D receptor gene polymorphisms with insulin
resistance and response to vitamin D. Metabolism 61,
293–301.
43. Skaaby T, Husemoen LL, Pisinger C, et al. (2012) Vitamin D
status and changes in cardiovascular risk factors: a prospective
study of a general population. Cardiology 123, 62–70.
44. Pilz S, Gaksch M, Kienreich K, et al. (2015) Effects of
vitamin D on blood pressure and cardiovascular risk factors:
a randomized controlled trial. Hypertension 65, 1195–1201.
45. Zittermann A, Frisch S, Berthold HK, et al. (2009) Vitamin D
supplementation enhances the beneficial effects of weight
loss on cardiovascular disease risk markers. Am J Clin Nutr
89, 1321–1327.
46. Challoumas D (2014) Vitamin D supplementation and lipid
profile: what does the best available evidence show?
Atherosclerosis 235, 130–139.
47. Wu Y, Li S & Zhang D (2013) Circulating 25-hydroxyvitamin D
levels and hypertension risk. Eur J Epidemiol 28, 611–616.
48. Kunutsor SK, Burgess S, Munroe PB, et al. (2014) Vitamin D
and high blood pressure: causal association or epiphenome-
non? Eur J Epidemiol 29, 1–14.
49. Geldenhuys S, Hart PH, Endersby R, et al. (2014) Ultraviolet
radiation suppresses obesity and symptoms of metabolic
syndrome independently of vitamin D in mice fed a
high-fat diet. Diabetes 63, 3759–3769.
50. Liu D, Fernandez BO, Hamilton A, et al. (2014) UVA irradia-
tion of human skin vasodilates arterial vasculature and lowers
blood pressure independently of nitric oxide synthase. J Invest
Dermatol 134, 1839–1846.
51. Black LJ, Anderson D, Clarke MW, et al. (2015) Analytical bias
in the measurement of serum 25-hydroxyvitamin d con-
centrations impairs assessment of vitamin D status in clinical
and research settings. PLOS ONE 10, e0135478.
52. Black LJ, Burrows SA, Jacoby P, et al. (2014) Vitamin D
status and predictors of serum 25-hydroxyvitamin D
concentrations in Western Australian adolescents. Br J Nutr
112, 1154–1162.
2002 L. J. Black et al.
